Skip to content
lifestyle.onebyfourstudio.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cervomed
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
September 10, 2026
CervoMed to Attend September Investor Conferences
September 8, 2026
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 10, 2026
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
August 4, 2026
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 12, 2026
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
June 10, 2026
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 24, 2026